Association of uncontrolled blood pressure in apparent treatment‐resistant hypertension with increased risk of major adverse cardiovascular events plus by George Bakris, Cindy Chen, Alicia K. Campbell, Veronica Ashton, Lloyd Haskell, Mukul Singhal

Get full text

Characteristics, management, and blood pressure control in patients with apparent resistant hypertension in the US by Eric M. Ammann, Ellen S. O’Brien, Dejan Milentijevic, Akshay A. Kharat, Darren A. Talbot, William Canovatchel, Lloyd Haskell, Nabil S. Andrawis

Get full text

Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial by Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M. Bauersachs, Scott D. Berkowitz, Lloyd Haskell, Elliot S. Barnathan, Marc P. Bonaca

Get full text

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis by Concetta Lipardi MD, PhD, C. Gregory Elliott MD, Chiara L. Sugarmann BSN, MSHS, Lloyd Haskell MD, Alex C. Spyropoulos MD, Gary E. Raskob PhD, Jianfeng Xu PhD, Wentao Lu PhD, Jessica Marsigliano BS, Theodore Spiro MD, Zhong Yuan MD, PhD, Shujian Wu MD, PhD, Elliot S. Barnathan MD

Get full text